the aid library

LIST OPTIONS

Filter

1398

Sort by:

Direction:

Download (1471)

View PDF (3417)

The Treatment of Diarrhoea

World Health Organization WHO (2005) C_WHO

A manual for physicians and other senior health workers. This fourth revision of the manual reflects recent clinical experience and research findings in diarrhoea case management. Compared to earlier versions, it includes revised guidelines on the management of children with acute diarrhoea using th... more

Download (1222)

View PDF (2921)

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module
recommended

Krause, S.; S. Chynoweth, D. Quick et al. Women's Refugee Commission, IAWG (2019) C1

The module is currently available in English, French, Nepali, Portuguese, Russian, and Spanish

Download (1064)

View PDF (1749)

Clinical Management Rape Survivors Developing Protocols

World Health Organization; UNHCR (2004) C_WHO

Developing protocols for use with refugees and internally displaced persons

Download (2498)

View PDF (2554)

Guide for Implementing the Monitoring-Training-Planning (MTP) Approach to Build Skills for Pharmaceutical Management

Rational Pharmaceutical Management Plus Program Management Sciences for Health; USAID (2009) CC

In the mid-1980s, recognizing the limitations of traditional training and that the knowledge and skills acquired are not necessarily applied back in the workplace, MSH developed the Monitoring‐Training-Planning (MTP) approach to assist the Ecuadorian Ministry of Health to implement its Child Survi... more

Download (1046)

View PDF (1642)

Developing Pharmacy Practice - A focus on patient care

Wiedenmayer, K. et al. World Health Organization (WHO), International Pharmaceutical Federation (FIP) (2006) C_WHO

English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to educate pharmacy students and to guide pharmacists in practice to update their skills. The handbook, which brings together practical tools and knowledge,... more

Download (1030)

View PDF (3855)

Rapid Health Assessment Protocols for Emergencies

World Health Organization WHO (1999) C_WHO

Download (1131)

View PDF (1788)

Indicators and Reference Data: A Practical Tool for Project Managers in Humanitarian Aid

Marie Theres Benner and K. Peter Schmitz Malteser International (2011)

Operational Guideline

Download (575)

View PDF (1301)

Management of severe malnutrition: a manual for physicians and other senior health workers

World Health Organization WHO (1999) C_WHO

This manual provides practical guidelines for the management of children with severe malnutrition. It seeks to promote the best available therapy so as to reduce the risk of death, shorten the length of time spent in hospital, and facilitate rehabilitation and full recovery. Emphasis is given to the... more

Download (814)

View PDF (1097)

HEALTH SYSTEMS FINANCING The path to universal coverage

World Health Organization (2010) C_WHO

Promoting and protecting health is essential to human welfare and sustained economic and social development. This was recognized more than 30 years ago by the Alma-Ata Declaration signatories, who noted that Health for All would contribute both to a better quality of life and also to global peace a... more

Download (283)

View PDF (212)

Hospital-based birth defects surveillance: facilitator guide

World Health Organization ( WHO), Regional Oﬃce for South-East-Asia (2016) C_WHO

Birth defect has been an emerging major cause of child mortality in the region. Scarcity of the birth defects information hampers policy decisions and control measures at national level. In order to create evidence for action for birth defects prevention in the region, WHO-SEARO in collaboration wit... more

Download (156)

View PDF (1082)

MSF الإرشادات السريرية. دليل التشخيص والعلاج
recommended

Médecins sans Frontières (MSF) (2022) C2

Clinical Guidelines. Diagnosis and Treatment Manual.

Download (77)

View PDF (551)

An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases

Brindha, J.; Balamurali, M.; Kaushik, C. Frontiers in Chemistry (2021) C1

Front Chem. 2021; 9: 622286. Published online 2021 Mar 12. doi: 10.3389/fchem.2021.622286

Download (110)

View PDF (163)

Chagas disease key facts

International Federation of Red Cross and Red Crescent Societies IFRC IFRC (2022) C1

About six to seven million people worldwide, mostly in Latin America, are estimated to be infected with Trypanosoma cruzi, the parasite that causes Chagas disease (WHO data from 2021). Chagas disease is found mainly in endemic areas of 21 Latin American countries. Chagas disease was once entirely ... more

Download (140)

View PDF (175)

Report 2022: pesticide residues in food: Joint FAO/WHO Meeting on Pesticide Residues

World Health Organisation (WHO) (2023) C_WHO

The annual Joint Meeting of the Food and Agriculture Organization of the United Nations (FAO) Panel of Experts on Pesticide Residues in Food and the Environment and the World Health Organization (WHO) Core Assessment Group on Pesticide Residues (JMPR) was held in Rome, Italy, from 13 to 22 September... more

Download (19)

View PDF (14)

WHO mid-term programmatic and financial report for 2016-2017 including audited financial statements for 2016

World Health Organisation (WHO) (2017) C_WHO

In an ambitious new era for health development under the 2030 Agenda for Sustainable Development, WHO and its partners have a solid foundation of success on which to build. Health plays a fundamental role in development and is the central focus of Sustainable Development Goal 3, “Ensure healthy ... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (86)

View PDF (101)

Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors

Budreviciute, A.; Damiati, S.; Khdr Sabir, D. et al. (2020) CC

Non-communicable diseases (NCDs) are of increasing concern for society and national governments, as well as globally due to their high mortality rate. The main risk factors of NCDs can be classified into the categories of self-management, genetic factors, environmental factors, factors of medical co... more

Download (3)

View PDF (3)

Management of Type 2 Diabetes Mellitus

Richardson, C.R.; Borgeson, J. R.; Harrison, V.; et al. National Library of Medicine (2021) CC2

The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio... more

Download (25)

View PDF (60)

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Chung, K. F.; Wenzel, S. E.; Brozek, J. L.; et al. (2022) CC2

The European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force on severe asthma includes an updated definition of severe asthma, a discussion of severe asthma phenotypes in relation to genetics, natural history, pathobiology and physiology, as well as sections on evaluation and tr... more

Download (24)

View PDF (14)

Silica-associated lung disease: An old-world exposure in modern industries

Barnes, H.; Goh, N. S. L.; Leong, T. L.; Hoy, R. Official Journal of the Asian Pacific Society of Respirology (2019) CC2

Silicosis is not a new disease; the impact of silica dust on respiratory function was observed by Hippocrates in 430 B.C. and in the 16th century by Agricol. In 1713, Rammazini described silicotic nodules in post-mortems of stone cutters presenting with respiratory symptoms. In the mid-late 1800s,... more

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module recommended

MSF الإرشادات السريرية. دليل التشخيص والعلاج recommended

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module
recommended

MSF الإرشادات السريرية. دليل التشخيص والعلاج
recommended